130 related articles for article (PubMed ID: 35929297)
1. Triptorelin-functionalized PEG-coated biosynthesized gold nanoparticles: Effects of receptor-ligand interactions on adhesion to triple negative breast cancer cells.
Uzonwanne VO; Navabi A; Obayemi JD; Hu J; Salifu AA; Ghahremani S; Ndahiro N; Rahbar N; Soboyejo W
Biomater Adv; 2022 May; 136():212801. PubMed ID: 35929297
[TBL] [Abstract][Full Text] [Related]
2. Investigation of adhesive interactions in the specific targeting of Triptorelin-conjugated PEG-coated magnetite nanoparticles to breast cancer cells.
Hu J; Youssefian S; Obayemi J; Malatesta K; Rahbar N; Soboyejo W
Acta Biomater; 2018 Apr; 71():363-378. PubMed ID: 29458110
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cellular uptake of LHRH-conjugated PEG-coated magnetite nanoparticles for specific targeting of triple negative breast cancer cells.
Hu J; Obayemi JD; Malatesta K; KoĊĦmrlj A; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2018 Jul; 88():32-45. PubMed ID: 29636136
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the adhesion of biosynthesized gold and conjugated gold/prodigiosin nanoparticles to triple negative breast cancer cells.
Dozie-Nwachukwu SO; Obayemi JD; Danyuo Y; Anuku N; Odusanya OS; Malatesta K; Soboyejo WO
J Mater Sci Mater Med; 2017 Aug; 28(9):143. PubMed ID: 28819929
[TBL] [Abstract][Full Text] [Related]
5. Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues.
Ezenwafor TC; Uzonwanne VO; Madukwe JUA; Amin SM; Anye VC; Obayemi JD; Odusanya OS; Soboyejo WO
J Mech Behav Biomed Mater; 2022 Dec; 136():105461. PubMed ID: 36195050
[TBL] [Abstract][Full Text] [Related]
6. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
[TBL] [Abstract][Full Text] [Related]
7. Nano-delivery of
Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
[TBL] [Abstract][Full Text] [Related]
8. Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells.
Obayemi JD; Hu J; Uzonwanne VO; Odusanya OS; Malatesta K; Anuku N; Soboyejo WO
J Mech Behav Biomed Mater; 2017 Apr; 68():276-286. PubMed ID: 28226310
[TBL] [Abstract][Full Text] [Related]
9. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Haynes B; Zhang Y; Liu F; Li J; Petit S; Kothayer H; Bao X; Westwell AD; Mao G; Shekhar MPV
Nanomedicine; 2016 Apr; 12(3):745-757. PubMed ID: 26563438
[TBL] [Abstract][Full Text] [Related]
10. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises.
Ahmad J; Ahamad J; Algahtani MS; Garg A; Shahzad N; Ahmad MZ; Imam SS
Expert Opin Drug Deliv; 2024 Feb; 21(2):229-244. PubMed ID: 38344809
[TBL] [Abstract][Full Text] [Related]
12. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer.
Her S; Cui L; Bristow RG; Allen C
Radiat Res; 2016 May; 185(5):549-62. PubMed ID: 27135970
[TBL] [Abstract][Full Text] [Related]
13. Auranofin-Loaded Chitosan Nanoparticles Demonstrate Potency against Triple-Negative Breast Cancer.
Afrifa MAO; Kim JH; Pitton KA; Olelewe C; Arojojoye AS; Strachan DR; Suckow MA; Awuah SG
ACS Appl Bio Mater; 2024 Mar; 7(3):2012-2022. PubMed ID: 38450675
[TBL] [Abstract][Full Text] [Related]
14. Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics.
Akter Z; Khan FZ; Khan MA
Curr Med Chem; 2023; 30(3):316-334. PubMed ID: 34477507
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
16. Triptorelin Tethered Multifunctional PAMAM-Histidine-PEG Nanoconstructs Enable Specific Targeting and Efficient Gene Silencing in LHRH Overexpressing Cancer Cells.
Tambe P; Kumar P; Karpe YA; Paknikar KM; Gajbhiye V
ACS Appl Mater Interfaces; 2017 Oct; 9(41):35562-35573. PubMed ID: 28949503
[TBL] [Abstract][Full Text] [Related]
17. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
18. Octaarginine-modified gold nanoparticles enhance the radiosensitivity of human colorectal cancer cell line LS180 to megavoltage radiation.
Zhang X; Wang H; Coulter JA; Yang R
Int J Nanomedicine; 2018; 13():3541-3552. PubMed ID: 29950834
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRH
Yousefvand M; Mohammadi Z; Ghorbani F; Irajirad R; Abedi H; Seyedi S; Papi A; Montazerabadi A
Contrast Media Mol Imaging; 2021; 2021():5534848. PubMed ID: 34104122
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
